Sentences with phrase «of androgen deprivation therapy»

All had been treated previously with at least one type of androgen deprivation therapy and had rising levels of prostate specific antigen (PSA), a blood marker for prostate cancer, and radiographic evidence their cancers were becoming resistant.

Not exact matches

«A significant number of advanced prostate cancer patients treated with a chemical castration therapy called androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic, castration - resistant prostate cancer,» said Ronald DePinho, M.D., professor of Cancer Biology.

Denmeade says the combination of drugs that block testosterone production and receptors, called androgen deprivation therapy, may make prostate cancer more aggressive over time by enabling prostate cancer cells to subvert attempts to block testosterone receptors.

Brachytherapy is an extremely efficient and safe radiation oncology modality, and this trial shows that it can have a wider field of applicability than simply in very localised and low risk tumours when combined with other techniques — in this case, androgen deprivation therapy and external bean radiation therapy.»

«There has been a groundswell of interest in the idea of reversing resistance to androgen deprivation therapy.

Twenty - two patients with elevated prostate - specific antigen and biopsy - proven prostate carcinoma who underwent MRI of the prostate at 1.5 T with endorectal coil were divided into two groups: those who were treated with androgen deprivation, radiation therapy, or both, and a Gleason - matched control group who had not received such therapy.

Preliminary results of a study of patients with prostate cancer show that MR tractography may be a reliable quantitative imaging biomarker to assess prostate cancer treatment response to androgen deprivation and radiation therapy, according to a team of researchers at Brigham and Women's Hospital and Massachusetts General Hospital in Boston.

The research teams, led by Nima Sharifi, M.D., of the Cleveland Clinic Lerner Research Institute, studied the role of the HSD3B1 (1245C) genetic variant in two different prostate cancer patient populations, following androgen deprivation therapy (ADT).

Androgen deprivation therapy is a powerful tool against prostate cancer, and more and more men are opting for the treatment as a growing array of hormone - based therapies become available.

A new Moffitt Cancer Center study indicated that men who are on androgen deprivation therapy have greater odds of experiencing impaired cognitive function.

«The risk of cognitive impairment should be considered when deciding whether or not to receive androgen deprivation therapy for prostate cancer,» said Brian Gonzalez, Ph.D., a postdoctoral fellow in the Health Outcomes and Behavior Program at Moffitt.

Long - term follow - up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival (OS) over ADT alone in metastatic hormone - sensitive prostate cancer (mHSPC) patients with high - volume disease.

A significant fraction of advanced PCa treated with androgen deprivation therapy experience relentless progression to lethal metastatic castration - resistant prostate cancer (mCRPC).

Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen - deprivation therapy.

A second phase 3 study presented Sunday found that adding radiation to hormone therapy, also known as androgen - deprivation therapy (ADT) in patients with locally advanced or high - risk prostate cancer reduced the seven - year risk of dying by 43 percent compared to treating with hormone therapy alone.

Two clinical trials of intermittent versus continuous androgen deprivation found that intermittent therapy reduced some of the side effects of hormone therapy, including those involving sexual function.

Researchers have investigated whether a technique called intermittent androgen deprivation can improve the effectiveness of hormone therapy for prostate cancer — that is, whether it delays the development of hormone resistance.